RT Journal
A1 Voelker R
T1 NIh program helps developers navigate path to new drugs for neglected diseases
JF JAMA
JO JAMA
YR 2012
FD February 8
VO 307
IS 6
SP 549
OP 550
DO 10.1001/jama.2012.83
UL http://dx.doi.org/10.1001/jama.2012.83
AB 
Since 2009, the NIH's Therapeutics for Rare and Neglected Diseases (TRND) program has solicited proposals from scientists and pharmaceutical companies trying to navigate that dead zone between discovering promising compounds and getting them into human clinical trials. To date, TRND has received 125 applications for nonmonetary assistance; 10 have gotten the green light.